Telomir Pharmaceuticals (TELO) filed an 8-K to share a press release about a peer-reviewed preclinical study of its drug candidate Telomir-Zn, published in the Journal of Oncology Research and Therapy. In laboratory models of prostate cancer and triple-negative breast cancer (TNBC), Telomir-Zn inhibited histone demethylases, reduced free intracellular iron, slowed primary tumor growth, and in one TNBC model it significantly cut metastatic spread. The study also showed that combining Telomir-Zn with paclitaxel produced a synergistic reduction in tumor growth in TNBC models.
View Full Filing (SEC EDGAR)